rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Caris Life Sciences, Inc.

CAI · Nasdaq

Health CareDiagnostics & LabsIn trendAISynthetic Biology / TechBio

CAI stood above a rising 150-day average in 5 of the last 35 weekly readings, including each of the last 5 weeks. It is 47.0% above that average now. Diagnostics & Labs: 48% of its 44 stocks in an uptrend (−2 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
5 in a row
Industry in uptrend
48% -2 in 4 wk
Insider buys, 12 months
$3.1M
Insider sales, 12 months
$56.1M
Officials’ trades on record
0
Institutions holding
229 (+39)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 35 weeks.

17 Apr – 16 Oct
20%38%55%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$52.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months5
Buyers · sellers4 · 4
WhoDidSharesTraded
John Russel DentonOfficersold7,500at $31.8222 Sep 2026filed 23 Sep 2026
Brian J. BrilleDirector, Officersold400,000at $30.3317 Sep 2026filed 17 Sep 2026
David Baxley SpetzlerPresidentsold119,212at $24.764 Sep 2026filed 4 Sep 2026
David Baxley SpetzlerPresidentsold393,100at $24.763 Sep 2026filed 4 Sep 2026
David Baxley SpetzlerPresidentsold84,900at $25.323 Sep 2026filed 4 Sep 2026
Jon HalbertDirectorbought68,000at $14.5615 May 2026filed 13 Jul 2026
Jeff L. VacircaDirectorbought31,050at $16.1511 May 2026filed 12 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders229+39 on the quarter
New · exited64 · 23
Reported value$2.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
FMR LLCadded · filed 13 Aug 202630,923,878$551.1M+138,293+0.4%
J. H. Whitney Equity Partners VI, LLCreduced · filed 12 Aug 202611,256,615$200.6M-7,000,000−38.3%
COATUE MANAGEMENT LLCunchanged · filed 14 Aug 20269,819,992$175.0M00.0%
BRAIDWELL LPadded · filed 14 Aug 20268,256,032$147.1M+246,585+3.1%
PointState Capital LPreduced · filed 14 Aug 20266,828,835$121.7M-531,611−7.2%
JPMORGAN CHASE & COnew · filed 12 Aug 20266,558,514$120.2M+6,558,514
BlackRock, Inc.added · filed 7 Aug 20265,536,798$98.7M+679,686+14.0%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20264,844,431$86.3M+1,085,969+28.9%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20264,280,238$76.3M+951,217+28.6%
LOS ANGELES CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,958,531$70.5M+1,668,929+72.9%
30 Jun 2025 – 30 Jun 2026
112169225Jun 25Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

John Russel Denton Company insiderOfficer · last 22 Sep 20262 · 1
Brian J. Brille Company insiderDirector, Officer · last 17 Sep 20261 · 1
David Baxley Spetzler Company insiderPresident · last 4 Sep 20261 · 2
David Paul Fredrickson Company insiderDirector · last 14 Aug 20260 · 0
Jeff L. Vacirca Company insiderDirector · last 14 Aug 20261 · 0
Jon Halbert Company insiderDirector · last 14 Aug 20261 · 0
Joseph E. Gilliam Company insiderDirector · last 14 Aug 20260 · 0
Laura I. Johansen Company insiderDirector · last 14 Aug 20260 · 0
Lloyd Minor Company insiderDirector · last 14 Aug 20260 · 0
Peter M. Castleman Company insiderDirector · last 14 Aug 20260 · 0
T. Danny Phillips Company insiderDirector · last 14 Aug 20260 · 0
George Poste Company insiderDirector · last 29 May 20260 · 0

Same industry

CDNA CareDxLeading+83%
XGN ExagenLeading+49%
NTRA NateraLeading+46%
PSNL PersonalisLeading+35%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 20255.6%
Free cash flow marginFY 2025 · to 31 Dec 20258.2%
Return on capital employedFY 2025 · to 31 Dec 20254.5%
Debt to equityFY 2025 · to 31 Dec 20250.66×
Interest coverFY 2025 · to 31 Dec 20250.79×
Research spendFY 2025 · to 31 Dec 202512.5%
Share count trendFY 2025 · to 26 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$796.3M
Free cash flowFY 2025 · to 31 Dec 2025$66.9M

Analyst forecasts

No analyst forecasts yet.